MedTrace Logo

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

NCT03729778 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-07-15

No results posted yet for this study

Summary

The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.

Conditions

Interventions

BIOLOGICAL

Prevnar-13

One time administration of prevnar-13 vaccine

Sponsors & Collaborators

  • VA Eastern Colorado Health Care System

    lead FED

Principal Investigators

  • Edward N Janoff, MD · University of Colorado Anschutz; Rocky Mountain Regional VAMC

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-18
Primary Completion
2027-01-01
Completion
2028-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03729778 on ClinicalTrials.gov